EP4384160A4 - HETEROCYCLICAL COMPOUNDS AND METHODS FOR USE - Google Patents
HETEROCYCLICAL COMPOUNDS AND METHODS FOR USEInfo
- Publication number
- EP4384160A4 EP4384160A4 EP22856568.5A EP22856568A EP4384160A4 EP 4384160 A4 EP4384160 A4 EP 4384160A4 EP 22856568 A EP22856568 A EP 22856568A EP 4384160 A4 EP4384160 A4 EP 4384160A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- heterocyclical
- compounds
- heterocyclical compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231543P | 2021-08-10 | 2021-08-10 | |
| US202163289579P | 2021-12-14 | 2021-12-14 | |
| PCT/US2022/039971 WO2023018812A1 (en) | 2021-08-10 | 2022-08-10 | Heterocyclic compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4384160A1 EP4384160A1 (en) | 2024-06-19 |
| EP4384160A4 true EP4384160A4 (en) | 2025-10-29 |
Family
ID=85201014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22856568.5A Pending EP4384160A4 (en) | 2021-08-10 | 2022-08-10 | HETEROCYCLICAL COMPOUNDS AND METHODS FOR USE |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4384160A4 (en) |
| JP (1) | JP2024532734A (en) |
| AU (1) | AU2022325771A1 (en) |
| CA (1) | CA3228310A1 (en) |
| MX (1) | MX2024001893A (en) |
| TW (1) | TW202330529A (en) |
| WO (1) | WO2023018812A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel phenol compound or salt thereof |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | Small-molecule inhibitors of KRAS mutant proteins |
| JP2025510572A (en) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | Methods for treating immunorefractory lung cancer |
| CN119585287A (en) | 2022-05-06 | 2025-03-07 | Paq医疗公司 | KRAS G12D proteolysis targeting chimera |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| IL316696A (en) | 2022-05-19 | 2024-12-01 | Genentech Inc | Aza-tetracyclic oxazepine compounds and uses thereof |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2023244600A1 (en) * | 2022-06-15 | 2023-12-21 | Mirati Therapeutics, Inc. | Prodrugs of pan-kras inhibitors |
| CN117327103A (en) * | 2022-07-01 | 2024-01-02 | 苏州泽璟生物制药股份有限公司 | Substituted pyrimido ring inhibitor and preparation method and application thereof |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024012519A1 (en) * | 2022-07-13 | 2024-01-18 | 北京华森英诺生物科技有限公司 | Pan-kras inhibitor |
| CN117624170A (en) * | 2022-08-24 | 2024-03-01 | 泰励生物科技（上海）有限公司 | Compounds with activity against KRAS mutated tumors |
| KR20250109197A (en) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | Spirocyclic dihydropyranopyrimidine KRas inhibitor |
| KR20250151412A (en) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Cereblon-based KRAS degradation protein and related uses |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (en) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| KR20250172857A (en) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Crystalline form of RAS inhibitor |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202515570A (en) | 2023-08-17 | 2025-04-16 | 美商樹線生物科學公司 | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202528315A (en) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | Spirocyclic dihydropyranopyridine kras inhibitors |
| WO2025076044A1 (en) | 2023-10-03 | 2025-04-10 | PAQ Therapeutics Inc. | Kras proteolysis targeting chimeras |
| TW202529804A (en) | 2023-10-06 | 2025-08-01 | 美商安進公司 | Combination therapy for cancer treatment |
| WO2025080593A1 (en) | 2023-10-09 | 2025-04-17 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025080592A1 (en) | 2023-10-09 | 2025-04-17 | Incyte Corporation | Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer |
| TW202530228A (en) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ras inhibitors |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194057A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025194054A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
| WO2025228384A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugates and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132200A1 (en) * | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| WO2022228568A1 (en) * | 2021-04-30 | 2022-11-03 | 劲方医药科技(上海)有限公司 | Pyridino- or pyrimido-cyclic compound, preparation method therefor and medical use thereof |
| WO2022248885A2 (en) * | 2021-05-28 | 2022-12-01 | Redx Pharma Plc. | Compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103588792B (en) * | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | Pyridopyrimidine or pyrimidopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof |
| WO2020146613A1 (en) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| JP7622043B2 (en) * | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12D inhibitors |
-
2022
- 2022-08-10 MX MX2024001893A patent/MX2024001893A/en unknown
- 2022-08-10 EP EP22856568.5A patent/EP4384160A4/en active Pending
- 2022-08-10 WO PCT/US2022/039971 patent/WO2023018812A1/en not_active Ceased
- 2022-08-10 TW TW111130111A patent/TW202330529A/en unknown
- 2022-08-10 AU AU2022325771A patent/AU2022325771A1/en active Pending
- 2022-08-10 JP JP2024507879A patent/JP2024532734A/en active Pending
- 2022-08-10 CA CA3228310A patent/CA3228310A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132200A1 (en) * | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| WO2022228568A1 (en) * | 2021-04-30 | 2022-11-03 | 劲方医药科技(上海)有限公司 | Pyridino- or pyrimido-cyclic compound, preparation method therefor and medical use thereof |
| WO2022248885A2 (en) * | 2021-05-28 | 2022-12-01 | Redx Pharma Plc. | Compounds |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2023018812A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022325771A1 (en) | 2024-02-15 |
| EP4384160A1 (en) | 2024-06-19 |
| JP2024532734A (en) | 2024-09-10 |
| TW202330529A (en) | 2023-08-01 |
| WO2023018812A1 (en) | 2023-02-16 |
| MX2024001893A (en) | 2024-02-29 |
| CA3228310A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4384160A4 (en) | HETEROCYCLICAL COMPOUNDS AND METHODS FOR USE | |
| EP4384159A4 (en) | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | |
| EP4384177A4 (en) | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | |
| EP3814503A4 (en) | COMPOUNDS AND METHODS FOR REDUCING LRRK2 EXPRESSION | |
| EP3589319A4 (en) | GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE | |
| EP3565520A4 (en) | Anhydrous compositions of MTOR inhibitors and method of use | |
| EP3518972A4 (en) | ANTIGEN-BINDING MOLECULES AND METHOD FOR USE THEREOF | |
| EP3983386A4 (en) | ACSS2 INHIBITORS AND METHODS OF USE | |
| EP4192476A4 (en) | COMPOUNDS AND METHODS FOR SCN2A MODULATION | |
| EP3755690A4 (en) | EGFR INHIBITORS AND METHOD OF USE THEREOF | |
| EP4405358A4 (en) | FGFR inhibitors and methods for using them | |
| EP3743060A4 (en) | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USING THEREOF | |
| EP4003363A4 (en) | INTERLINKING COMPOUNDS AND METHODS OF USE THEREOF | |
| EP3541847A4 (en) | GLYCAN INTERACTING COMPOUNDS AND METHOD FOR USE | |
| EP4139296C0 (en) | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | |
| EP4401764A4 (en) | ANTI-SIGLEC-6 ANTIBODIES AND METHOD FOR USE THEM | |
| EP4426314A4 (en) | PI3K-ALPHA INHIBITORS AND METHODS FOR THE PREPARATION AND USE THEREOF | |
| EP4396352A4 (en) | Compounds and methods for reducing DMPK expression | |
| EP4412617A4 (en) | Novel Pikfyve inhibitors and methods for using them | |
| EP4291651A4 (en) | Compounds and methods for reducing PLN expression | |
| EP3983400C0 (en) | QUINAZOLINYLINE COMPOUNDS AND METHODS OF USE | |
| EP4034099A4 (en) | PIMOBENDAN FORMULATION AND METHOD OF USE THEREOF | |
| EP3941909A4 (en) | PI4-KINASE INHIBITORS AND METHODS OF USE THEREOF | |
| EP3781465C0 (en) | LOCKING DEVICE AND METHOD FOR USE OF IT | |
| EP3817693C0 (en) | ORTHETIC ARCH SUPPORT DEVICE AND METHOD OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240227 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250925 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/33 20060101AFI20250919BHEP Ipc: A61K 31/395 20060101ALI20250919BHEP Ipc: A61K 31/519 20060101ALI20250919BHEP |